Definition: PSMA7 (Proteasome Subunit Alpha Type 7) is a 28 kDa protein encoded by the PSMA7 gene located at chromosome 20q13.33 . It forms part of the 20S core proteasome complex, which comprises two outer α-rings and two inner β-rings .
Forms the α-ring "gate" regulating substrate entry into the proteolytic chamber .
Facilitates ATP/ubiquitin-dependent degradation of misfolded proteins and regulatory factors (e.g., cyclins, transcription factors) .
Binds hepatitis B virus X protein (HBx) and modulates hepatitis C virus IRES activity, enhancing viral replication .
Regulates hypoxia-inducible factor 1α (HIF-1α), influencing cellular responses to oxygen deprivation .
Activates NF-κB and MAPK pathways to promote proliferation .
Interacts with PLK1 and HIF1A, driving cell cycle progression and angiogenesis .
Expression: E. coli-derived PSMA7 (30 kDa with N-terminal His-tag) .
Purity: >90% via chromatography; formulated in Tris-HCl/NaCl/glycerol .
Antibodies: Mouse monoclonal IgG1 (Clone 67817-1-Ig) validated for WB, IHC, and flow cytometry .
Knockdown Models: shRNA-mediated PSMA7 silencing reduces anchorage-independent growth in RKO colorectal cells .
PSMA7 is part of the alpha ring of the proteasome, contributing to the formation of heptameric alpha rings and the substrate entrance gate . The 20S proteasome complex, in association with different regulatory particles, forms the 26S proteasome. This complex is essential for the ATP-dependent degradation of ubiquitinated proteins, which is crucial for maintaining protein homeostasis by removing misfolded or damaged proteins .
PSMA7 is involved in various cellular processes, including:
Recombinant PSMA7 is used in research to study its structure, function, and role in various diseases. Understanding its mechanisms can lead to the development of new therapeutic strategies for diseases associated with proteasome dysfunction.